US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings

1.01

+0.03163.23%

Post-market: 0.9920-0.0180-1.78%19:59 EDT

Volume:772.28K

Turnover:778.18K

Market Cap:185.73M

PE:-14.42

High:1.03

Open:0.9895

Low:0.9700

Close:0.9784

Loading ...

Overview Company News Filings

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission

Tevogen Bio Holdings Delays Annual Report Filing

Press Release: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

Tevogen Bio Files New US Patent for T Cell Vaccine Under Development

MT Newswires Live

BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO

Tevogen announces new patent filed for T cell vaccine

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent With the Uspto

THOMSON REUTERS

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Have Tevogen Bio Holdings Insiders Been Selling Stock?

Simply Wall St.

Tevogen Bio Holdings Initiated at Buy by D. Boral Capital

BRIEF-Tevogen Bio To Receive $8 Mln Of Non-Dilutive Grant Funding

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

THOMSON REUTERS

Press Release: Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Press Release: Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen CEO addresses broader implications of short-selling

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen Bio Meets Barda Techwatch Team, Highlighting Exactcell™ Technology’s Potential as a Scalable Medical Countermeasure

THOMSON REUTERS

Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration

Tevogen Bio Holdings Secures Funding for Therapeutics and AI

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVGN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":1.01,"timestamp":1746216000000,"preClose":0.9784,"halted":0,"volume":772284,"hourTrading":{"tag":"盘后","latestPrice":0.992,"preClose":1.01,"latestTime":"19:59 EDT","volume":29907,"amount":29866.2064,"timestamp":1746230399310},"delay":0,"floatShares":22757419,"shares":183893433,"eps":-0.070045,"marketStatus":"Market Closed","change":0.0316,"latestTime":"05-02 16:00:00 EDT","open":0.9895,"high":1.03,"low":0.97,"amount":778181.0061672,"amplitude":0.061325,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.070045,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9784,"preHourTrading":{"tag":"盘前","latestPrice":0.98,"preClose":0.9784,"latestTime":"09:23 EDT","volume":8404,"amount":8138.594956800001,"timestamp":1746192222253},"postHourTrading":{"tag":"盘后","latestPrice":0.992,"preClose":1.01,"latestTime":"19:59 EDT","volume":29907,"amount":29866.2064,"timestamp":1746230399310},"volumeRatio":0.16018872693681308},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","floatShares":22757419,"roa":"-746.67%","roe":"--","lyrEps":-0.070045,"volumeRatio":0.16018872693681308,"shares":183893433,"dividePrice":0,"high":1.03,"amplitude":0.061325,"preClose":0.9784,"low":0.97,"week52Low":0.2556,"pbRate":"-12.00","week52High":3.09,"institutionHeld":0,"latestPrice":1.01,"eps":-0.070045,"divideRate":0,"volume":772284,"delay":0,"ttmEps":-0.070045,"open":0.9895,"prevYearClose":1.03,"prevWeekClose":0.9922,"prevMonthClose":1.03,"prevQuarterClose":1.08,"fiveDayClose":0.9922,"twentyDayClose":1,"sixtyDayClose":1.48},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525798450","title":"Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission","url":"https://stock-news.laohu8.com/highlight/detail?id=2525798450","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525798450?lang=en_us&edition=fundamental","pubTime":"2025-04-08 03:58","pubTimestamp":1744055880,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 07, 2025  -- Tevogen  , a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, is unified by a commitment to advancing patient-centric solutions. The Company’s clinical-stage immunotherapy effort, Tevogen Bio, focuses on the development of off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers. Its artificial intelligence effort, Tevogen.AI, aims to advance innovation in drug discovery, clinical trial efficiency, and patient access. Together, these efforts represent the foundational pillars of Tevogen’s broader vision to redefine the future of medicine.With this in mind, Tevogen today highlights the significant number of shares held by executive officers and members of the board of directors of the Company, emphasizing their conviction of the mission and progress of Tevogen. The insiders own approximately 74% of the outstanding shares, a unique advantage as compared to other similar companies ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-highlights-most-recent-195800476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":1},{"id":"2524447148","title":"Tevogen Bio Holdings Delays Annual Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524447148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524447148?lang=en_us&edition=fundamental","pubTime":"2025-04-01 22:21","pubTimestamp":1743517301,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings ( ($TVGN) ) has released a notification of late filing. Tevogen Bio Holdings Inc. has announced a delay in filing its Form 10-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tevogen-bio-holdings-delays-annual-report-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tevogen-bio-holdings-delays-annual-report-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2522889098","title":"Press Release: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522889098","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522889098?lang=en_us&edition=fundamental","pubTime":"2025-03-26 01:11","pubTimestamp":1742922660,"startTime":"0","endTime":"0","summary":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan. WARREN, N.J., March 25, 2025  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access.Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2430703251.USD","IE00B1BXHZ80.USD","LU0795875086.SGD","TVGN","BK4581","IE00B42XCP33.USD","BK4504","LU2089984988.USD","SG9999001440.SGD","LU0912757837.SGD","BK4585","LU0114720955.EUR","LU1244550577.SGD","LU1430594728.SGD","LU2468319806.SGD","SG9999002232.USD","LU1244550494.USD","BK4139","LU2592432038.USD","LU2505996509.AUD","LU0203345920.USD","LU0466842654.USD","LU1221951129.SGD","IE0002270589.USD","LU1585245621.USD","LU1894683264.USD","LU1023059063.AUD","LU1066051811.HKD","LU2112291526.USD","LU2430703178.SGD","IE0034235303.USD","IE000M9KFDE8.USD","LU0203347892.USD","BK4559","IE00B3PB1722.GBP","LU1718418525.SGD","JNJ","IE00BVYPNW00.USD","IE00BSNM7G36.USD","LU0795875169.SGD","BK4588","LU1267930813.SGD","LU2129689514.USD","LU1261432733.SGD","LU0792757196.USD","LU2505996681.GBP","LU0098860793.USD","LU0882574055.USD","IE0009355771.USD","BK4550"],"gpt_icon":0},{"id":"2518717860","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2518717860","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518717860?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:20","pubTimestamp":1741692000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 07:20 ET (11:20 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2518208702","title":"Tevogen Bio Files New US Patent for T Cell Vaccine Under Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208702","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518208702?lang=en_us&edition=fundamental","pubTime":"2025-03-11 01:18","pubTimestamp":1741627092,"startTime":"0","endTime":"0","summary":"Tevogen Bio  said Monday it filed a new patent with the US Patent and Trademark Office for its T cell vaccine that is currently under development.The company said the vaccine's design aims to use its Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate a T cell response, unlike vaccines that mainly induce a B cell response.Tevogen Bio said that similar to its lead product candidate TVGN 489, the vaccine can target the entire viral genome, helping to mitigate a risk posed by mutations.The company's shares were down over 5% in recent trading.Price: 1.08, Change: -0.06, Percent Change: -5.09","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2518208975","title":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518208975?lang=en_us&edition=fundamental","pubTime":"2025-03-11 01:06","pubTimestamp":1741626362,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTOMarch 10 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO ANNOUNCES UNIQUE T CELL VACCINE UNDER DEVE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2518203871","title":"Tevogen announces new patent filed for T cell vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2518203871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518203871?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:45","pubTimestamp":1741625135,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) Bio announced the filing of a new patent with the U.S. Patent and Trademark Office for its under-development T cell vaccine. “Unlike...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-announces-new-patent-filed-for-t-cell-vaccine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-announces-new-patent-filed-for-t-cell-vaccine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2518270844","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent With the Uspto","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270844?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624832,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2518270671","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270671","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270671?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624800,"startTime":"0","endTime":"0","summary":"Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.The company hopes to address public concerns about inoculation during vaccine development.Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibilit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-unique-t-164000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2518828026","title":"Have Tevogen Bio Holdings Insiders Been Selling Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518828026","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518828026?lang=en_us&edition=fundamental","pubTime":"2025-03-09 22:01","pubTimestamp":1741528861,"startTime":"0","endTime":"0","summary":"We'd be surprised if Tevogen Bio Holdings Inc. ( NASDAQ:TVGN ) shareholders haven't noticed that the Chief Scientific...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvgn/tevogen-bio-holdings/news/have-tevogen-bio-holdings-insiders-been-selling-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2516767384","title":"Tevogen Bio Holdings Initiated at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2516767384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516767384?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:20","pubTimestamp":1741090800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 07:20 ET (12:20 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2516366388","title":"BRIEF-Tevogen Bio To Receive $8 Mln Of Non-Dilutive Grant Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2516366388","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516366388?lang=en_us&edition=fundamental","pubTime":"2025-03-04 04:30","pubTimestamp":1741033847,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio To Receive $8 Mln Of Non-Dilutive Grant FundingMarch 3 (Reuters) - Tevogen Bio:TEVOGEN BIO TO RECEIVE $8 MILLION OF NON-DILUTIVE GRANT FUNDING, REITERATES EFFICIENT OPERATIONSSource text: ID:nGNXBPqPTFurther company coverage: MSFT.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2516565133","title":"Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2516565133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516565133?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:52","pubTimestamp":1741024371,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064131342.USD","LU2505996681.GBP","LU0545039389.USD","LU1046421795.USD","LU1119994496.HKD","IE00BKDWB100.SGD","LU0096364046.USD","LU1814569148.SGD","LU2461242641.AUD","LU0757359954.USD","IE00BWXC8680.SGD","LU0225283273.USD","BK4577","LU0310800379.SGD","SG9999014880.SGD","LU0094547139.USD","LU0345769128.USD","LU0426417589.USD","LU2095319765.USD","IE00BBT3K403.USD","LU0640476718.USD","LU2213496289.HKD","MSFT","LU0345770308.USD","LU0994945656.USD","LU0426412945.USD","LU1032955483.USD","LU2360032135.SGD","LU0960925559.SGD","LU1868836757.USD","BK4503","LU0080751232.USD","LU0203201768.USD","IE00BMPRXR70.SGD","LU0787776722.HKD","LU2471134523.USD","IE0034235188.USD","LU0353189763.USD","LU1003077747.HKD","LU0545562505.USD","IE0009G5SDU7.USD","LU1301847155.USD","TVGN","LU1791710400.SGD","LU1037948897.HKD","LU1697837992.HKD","LU0096362180.USD","LU0354030438.USD","LU1989764664.SGD","LU0175139822.USD"],"gpt_icon":0},{"id":"2516651568","title":"Press Release: Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2516651568","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516651568?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:52","pubTimestamp":1741024320,"startTime":"0","endTime":"0","summary":"-- Tevogen Bio will receive the remaining $8 million grant, totaling $10. million, from KRHP LLC this quarter, following a positive review of its. -- Efficient operations with operating expenses of $9.7 million for the. expanded datasets and wet lab science to enhance predictive modeling. \"Tevogen Bio's disciplined business model is designed for long-term success without reliance on excessive capital raises or shareholder dilution. This additional $8 million in non-dilutive funding reinforces the efficiency and sustainability of our approach, which we believe must be the new standard in biotech,\" commented Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio.Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large pati","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2511616394","title":"Press Release: Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2511616394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511616394?lang=en_us&edition=fundamental","pubTime":"2025-02-15 02:16","pubTimestamp":1739556960,"startTime":"0","endTime":"0","summary":"Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency. WARREN, N.J., Feb. 14, 2025  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange.-- On October 29, Tevogen Bio signed a letter of intent with CD8 Technology. Services to build an up to $50 million turn-key research and development. facility for Tevogen Bio's use. This arrangement, when finalized, will. -- On August 15, Tevogen Bio entered into a definitive agreement for a $6. million Series C Preferred Stock investment . The shares of. the Series C have a 7.5% annual dividend and are convertible into shares. of common stock after 6 months, at the election of the holder. The Series. -- On June 11, Tevogen Bio entered into a definitive agreement for up to $50. million in financing, consisting of a $36 m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2511069028","title":"Tevogen CEO addresses broader implications of short-selling","url":"https://stock-news.laohu8.com/highlight/detail?id=2511069028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511069028?lang=en_us&edition=fundamental","pubTime":"2025-02-15 01:01","pubTimestamp":1739552466,"startTime":"0","endTime":"0","summary":"Tevogen Bio (TVGN) issued a statement from its Founder and CEO Ryan Saadi regarding broader implications of short-selling. “Tevogen Bio is committe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-ceo-addresses-broader-implications-of-short-selling?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-ceo-addresses-broader-implications-of-short-selling?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2510581991","title":"Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2510581991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510581991?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:30","pubTimestamp":1739226600,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Feb. 10, 2025  -- Tevogen Bio  , is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.With the concern of Chinese pharmaceutical companies developing drugs at a faster pace and lower cost, the U.S. biotech sector faces pressure to adapt. At the same time, Robert F. Kennedy Jr., who is soon to helm the Department of Health and Human Services, has prioritized affordable healthcare, prompting industry-wide discussions on sustainability and access. Built with these industry themes in mind, Tevogen Bio exemplifies how American biotech can remain competitive and thrive amid growing concerns surrounding affordability, efficiency, and global competition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bios-business-model-addresses-223000195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2509423773","title":"Tevogen Bio Meets Barda Techwatch Team, Highlighting Exactcell™ Technology’s Potential as a Scalable Medical Countermeasure","url":"https://stock-news.laohu8.com/highlight/detail?id=2509423773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509423773?lang=en_us&edition=fundamental","pubTime":"2025-02-08 03:56","pubTimestamp":1738958217,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY1AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2507520657","title":"Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2507520657","media":"Insider Monkey","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507520657?lang=en_us&edition=fundamental","pubTime":"2025-01-30 03:33","pubTimestamp":1738179198,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 10 Trending AI Stocks on Latest News. In this article, we are going to take a look at where Tevogen Bio Holdings Inc.  stands against other top trending AI stocks on latest news.The bloodbath that triggered one of the biggest routs in US stock markets appears to be under control. Even as people across China hail the success of their homegrown tech startup DeepSeek, it’s becoming increasingly clear there is room for everyone in the artificial intelligence race. That’s the sentiment echoed across the board as it becomes clear markets might have overreacted on reports China is at the forefront of developing AI models at the lowest costs possible.The reason is simple: our research has shown that we can outperform the market by imitating the top st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-holdings-inc-tvgn-193318272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSFT","TVGN","TVGNW"],"gpt_icon":1},{"id":"2507524408","title":"Tevogen Bio Holdings Secures Funding for Therapeutics and AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2507524408","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507524408?lang=en_us&edition=fundamental","pubTime":"2025-01-29 06:18","pubTimestamp":1738102697,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings ( ($TVGN) ) just unveiled an announcement. On January 28, 2025, Tevogen Bio Holdings Inc. announced it received an initial $2 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tevogen-bio-holdings-secures-funding-for-therapeutics-and-ai?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tevogen-bio-holdings-secures-funding-for-therapeutics-and-ai?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":78,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGN","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVGN","date":"2025-05-01","current":-13.797989,"percent":0.625899,"low":-87.683882,"twenty":-32.748667,"median":-22.02776,"eighty":-7.830197,"high":-2.106753,"avg":-22.902346,"sd":16.152967,"marketCap":189410235},"quantilePoints":[{"date":"2024-03-01","current":-58.029616,"twenty":-57.969868,"median":-57.58151,"eighty":-55.109463,"marketCap":1279054027},{"date":"2024-03-08","current":-55.116932,"twenty":-57.969868,"median":-57.3948,"eighty":-55.049716,"marketCap":1214854404},{"date":"2024-03-15","current":-48.544723,"twenty":-57.715942,"median":-55.116932,"eighty":-49.664986,"marketCap":1069993717},{"date":"2024-03-22","current":-31.890149,"twenty":-57.596447,"median":-52.465643,"eighty":-44.108482,"marketCap":702903564},{"date":"2024-03-28","current":-25.919148,"twenty":-57.357457,"median":-49.38492,"eighty":-32.983824,"marketCap":571294337},{"date":"2024-04-05","current":-25.392625,"twenty":-55.998205,"median":-48.543977,"eighty":-28.607629,"marketCap":559689021},{"date":"2024-04-12","current":-18.446995,"twenty":-55.146806,"median":-35.064227,"eighty":-23.267262,"marketCap":406597612},{"date":"2024-04-19","current":-15.833048,"twenty":-54.915285,"median":-32.71989,"eighty":-19.118705,"marketCap":348982566},{"date":"2024-04-26","current":-6.348156,"twenty":-53.503754,"median":-29.329228,"eighty":-17.595595,"marketCap":139922255},{"date":"2024-05-03","current":-7.365355,"twenty":-52.428301,"median":-25.919148,"eighty":-15.026459,"marketCap":162342739},{"date":"2024-05-10","current":-2.698495,"twenty":-50.822591,"median":-23.061357,"eighty":-9.708944,"marketCap":163198734},{"date":"2024-05-17","current":-2.422494,"twenty":-49.291565,"median":-20.164731,"eighty":-7.316959,"marketCap":146506832},{"date":"2024-05-24","current":-2.231961,"twenty":-48.694091,"median":-18.372311,"eighty":-2.71254,"marketCap":134983822},{"date":"2024-05-31","current":-2.106753,"twenty":-48.544425,"median":-17.961548,"eighty":-2.656034,"marketCap":127411559},{"date":"2024-06-07","current":-8.033143,"twenty":-47.558444,"median":-17.550785,"eighty":-2.656034,"marketCap":148265257},{"date":"2024-06-14","current":-7.903098,"twenty":-44.108482,"median":-15.833048,"eighty":-2.68298,"marketCap":145865070},{"date":"2024-06-21","current":-6.795171,"twenty":-36.221832,"median":-12.47226,"eighty":-2.696046,"marketCap":125416385},{"date":"2024-06-28","current":-6.570165,"twenty":-35.295748,"median":-12.322891,"eighty":-2.697026,"marketCap":121263525},{"date":"2024-07-05","current":-6.173255,"twenty":-33.757254,"median":-8.033143,"eighty":-2.703177,"marketCap":113937879},{"date":"2024-07-12","current":-6.299258,"twenty":-33.071802,"median":-7.830197,"eighty":-2.721904,"marketCap":116263481},{"date":"2024-07-15","current":-6.435162,"twenty":-32.983824,"median":-7.830197,"eighty":-2.721904,"marketCap":118771808},{"date":"2024-08-02","current":-5.57114,"twenty":-32.895846,"median":-7.830197,"eighty":-2.721904,"marketCap":102824824},{"date":"2024-08-09","current":-5.526139,"twenty":-32.222045,"median":-7.468419,"eighty":-3.563104,"marketCap":101994252},{"date":"2024-08-16","current":-20.612899,"twenty":-30.545833,"median":-7.468046,"eighty":-4.127144,"marketCap":122353801},{"date":"2024-08-23","current":-17.275162,"twenty":-29.265149,"median":-7.830197,"eighty":-4.681198,"marketCap":102541700},{"date":"2024-08-30","current":-14.308285,"twenty":-28.407028,"median":-7.866648,"eighty":-5.281333,"marketCap":84930944},{"date":"2024-09-06","current":-12.936966,"twenty":-27.171154,"median":-9.617885,"eighty":-5.454137,"marketCap":76791088},{"date":"2024-09-13","current":-14.230663,"twenty":-25.708539,"median":-12.097501,"eighty":-5.499138,"marketCap":84470197},{"date":"2024-09-20","current":-12.649478,"twenty":-24.871927,"median":-12.454498,"eighty":-5.544139,"marketCap":75084620},{"date":"2024-09-27","current":-11.784139,"twenty":-23.267262,"median":-12.36199,"eighty":-5.658262,"marketCap":69948149},{"date":"2024-10-04","current":-8.756889,"twenty":-21.942215,"median":-12.240382,"eighty":-5.887588,"marketCap":51979034},{"date":"2024-10-11","current":-9.208245,"twenty":-21.329829,"median":-12.040003,"eighty":-6.069393,"marketCap":54658190},{"date":"2024-10-18","current":-39.673363,"twenty":-24.871927,"median":-12.127687,"eighty":-6.141394,"marketCap":235492672},{"date":"2024-10-25","current":-73.596963,"twenty":-29.393307,"median":-12.327491,"eighty":-6.173255,"marketCap":436855971},{"date":"2024-10-31","current":-70.722082,"twenty":-31.779361,"median":-12.436737,"eighty":-6.180635,"marketCap":419791285},{"date":"2024-11-08","current":-32.773648,"twenty":-33.757254,"median":-12.633666,"eighty":-6.224556,"marketCap":194537424},{"date":"2024-11-15","current":-42.548244,"twenty":-38.983392,"median":-12.936966,"eighty":-6.285578,"marketCap":252557358},{"date":"2024-11-22","current":-36.270609,"twenty":-39.155884,"median":-13.187081,"eighty":-6.299438,"marketCap":287084045},{"date":"2024-11-29","current":-28.972255,"twenty":-38.235922,"median":-13.602501,"eighty":-6.300158,"marketCap":229317133},{"date":"2024-12-06","current":-23.222036,"twenty":-37.373458,"median":-13.816575,"eighty":-6.348156,"marketCap":183803809},{"date":"2024-12-13","current":-22.337387,"twenty":-36.270609,"median":-14.269474,"eighty":-6.435162,"marketCap":176801759},{"date":"2024-12-20","current":-21.33331,"twenty":-36.221832,"median":-15.004006,"eighty":-6.508963,"marketCap":168854432},{"date":"2024-12-27","current":-23.222036,"twenty":-35.303209,"median":-15.833048,"eighty":-6.557925,"marketCap":183803809},{"date":"2025-01-03","current":-23.443198,"twenty":-34.373394,"median":-17.065337,"eighty":-6.580965,"marketCap":185554321},{"date":"2025-01-10","current":-28.52993,"twenty":-33.790638,"median":-17.550785,"eighty":-6.670967,"marketCap":225816108},{"date":"2025-01-17","current":-26.760632,"twenty":-33.439732,"median":-17.684618,"eighty":-6.873653,"marketCap":211812008},{"date":"2025-01-24","current":-30.52039,"twenty":-33.171426,"median":-18.032197,"eighty":-7.005548,"marketCap":241570720},{"date":"2025-01-31","current":-29.635741,"twenty":-33.528197,"median":-18.446995,"eighty":-7.075423,"marketCap":234568670},{"date":"2025-02-07","current":-31.405039,"twenty":-33.171426,"median":-19.295444,"eighty":-7.138439,"marketCap":248572770},{"date":"2025-02-14","current":-34.501311,"twenty":-33.892862,"median":-20.164731,"eighty":-7.192457,"marketCap":273079945},{"date":"2025-02-21","current":-34.280148,"twenty":-34.280148,"median":-20.612899,"eighty":-7.244366,"marketCap":271329432},{"date":"2025-02-28","current":-27.645281,"twenty":-34.280148,"median":-21.570546,"eighty":-7.365355,"marketCap":218814058},{"date":"2025-03-07","current":-24.327847,"twenty":-34.058986,"median":-22.031836,"eighty":-7.370735,"marketCap":192556371},{"date":"2025-03-14","current":-24.54901,"twenty":-33.906622,"median":-22.226806,"eighty":-7.443187,"marketCap":194306884},{"date":"2025-03-21","current":-25.875983,"twenty":-33.837824,"median":-22.558549,"eighty":-7.452187,"marketCap":204809958},{"date":"2025-03-28","current":-26.53947,"twenty":-33.616662,"median":-23.000874,"eighty":-7.454567,"marketCap":210061496},{"date":"2025-04-04","current":-13.396106,"twenty":-33.174337,"median":-23.222036,"eighty":-7.467672,"marketCap":183893433},{"date":"2025-04-11","current":-13.396106,"twenty":-33.15978,"median":-22.669131,"eighty":-7.468419,"marketCap":183893433},{"date":"2025-04-17","current":-13.664028,"twenty":-32.994496,"median":-22.447968,"eighty":-7.468419,"marketCap":187571301},{"date":"2025-04-25","current":-13.530067,"twenty":-32.809553,"median":-22.063146,"eighty":-7.757841,"marketCap":185732367},{"date":"2025-05-01","current":-13.797989,"twenty":-32.748667,"median":-22.02776,"eighty":-7.830197,"marketCap":189410235}],"updateTime":1746255991560}}}